INTRODUCTION AND OBJECTIVES: Active surveillance (AS)
is an established treatment modality for select men with prostate cancer (PC). Eligibility criteria are based on clinicopathologic features including PSA and Gleason grade. Prior studies have validated a combined cellcycle progression risk (CCR) score, which combines cell-cycle progression (CCP) gene expression data with the Cancer of the Prostate Risk Assessment (CAPRA) score to add significant prognostic discrimination to newly diagnosed PCs. Our objective was to assess the value of the CCR score for identifying men with higher risk clinicopathologic characteristics who qualify for AS.
METHODS: Prostate biopsy samples from 17,017 men were submitted by their physicians for CCP testing (Myriad Genetic Laboratories). The CCP score was calculated from RNA expression of 46 genes (31 CCP and 15 housekeeping genes), and combined with CAPRA to generate the CCR score. Clinicopathological data was obtained from physician-completed test request forms. A threshold CCR score of 0.8 was previously developed and validated in a cohort of conservatively managed men (survival data censored at 10 yrs). We evaluated the proportion of men eligible for AS based on their CCR score whose clinicopathologic criteria would traditionally disqualify them from AS: PSA>10ng/mL, Gleason grade group2 (Gleason Score 3+4), higher AUA risk.
RESULTS: Overall, 66.6% of clinically tested men qualified for AS based on their CCR score. Table 1 shows that a proportion of tested men with higher risk clinicopatholic features qualified for AS based on their CCR score, including AUA intermediate (42.9%) and high (14.1%) risk as well as Gleason grade group 2 (48.8%) and Gleason grade group >2 (1-3%). In addition, 48% of men with Gleason score 6 and PSA >10 ng/mL qualified for AS.
CONCLUSIONS: Clinical characteristics and Gleason grade are often used as stand-alone indicators to offer men with localized PC immediate definitive treatment rather than AS. However, our study demonstrates that a significant proportion of men who qualify for AS based on their CCR score have a range of PSA and Gleason grade prostate cancer that may not traditionally be considered for AS. This supports using CCR score to improve risk stratification in PC and identify men for AS. There is growing interest among urologists in the community about the extent to which prostate cancer (CaP) genomic tests can further risk stratify men who are candidates for active surveillance (AS). In this context, we evaluated the relationship between results from the Prolaris cell cycle progression genomics test and the frequency of adverse pathological outcomes among men treated with radical prostatectomy (RP) in a large, community-based practice.
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PD28-03 CORRELATION BETWEEN A GENOMICS TEST AND ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY AMONG ACTIVE SURVEILLANCE CANDIDATES
METHODS: For all patients undergoing Prolaris testing in a large urology practice from 7/2013 through 4/2016, we linked test results with clinical data from the Michigan Urological Surgery Improvement Collaborative (MUSIC) clinical registry. We then identified all men that met the published MUSIC appropriateness criteria for AS (i.e., any Gleason Score (GS) ¼6 or GS 3+4 with ¼3 positive cores and no more than 50% of any core involved), and also underwent RP as primary therapy. Genomic test results with an estimated 10-year CaP-specific mortality >3% were classified as high-risk. We then compared the frequency of adverse pathological outcomes with RP e defined as the presence of primary Gleason pattern 4 or 5 cancer and/or pathological stage T3 or T4 disease e among men with high-versus low-risk genomics results. RESULTS: We identified 118 patients who were candidates for AS based on MUSIC criteria, had a Prolaris test, and primary treatment with RP. Among the entire group, 49 (42%) and 69 patients (58%) had low and high-risk genomics results, respectively. When limited to patients with only GS 6 cancer on diagnostic biopsy (n¼26), only 4 men (15%) had high-risk Prolaris results. For the entire cohort (Figure 1a) , patients with high-risk genomic results were more likely to have pathological stage T3 or T4 tumors (36.2% vs 12.2%, p ¼0.004). Among the Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e517 men with only GS 6 cancer on biopsy, none of the 22 patients with a low-risk genomics result had primary pattern 4 or 5 cancer (Figure 1b) . CONCLUSIONS: Among patients seen in a large, community practice who are candidates for AS, high-risk results from a cell cycle progression genomics test are more frequently associated with the presence of T3 or T4 disease at RP. Our findings suggest a potentially useful role for these tests in further risk-stratifying men considering AS for early-stage CaP.
Source of Funding: Blue Cross and Blue Shield of Michigan and grant 1T32-CA180984 from the National Cancer Institute.
PD28-04 THE INFLUENCE OF PSYCHOSOCIAL CONSTRUCTS ON THE ADHERENCE TO ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER IN A PROSPECTIVE, POPULATION-BASED COHORT
Maximilian Lang, Mark Tyson*, JoAnn Alvarez, Tatsuki Koyama, Nashville, TN; Karen Hoffman, Houston, TX; Matthew Resnick, Nashville, TN; Matthew Cooperberg, San Francisco, CA; Xiao-Cheng Wu, Vivien Chen, New Orleans, LA; Lisa Paddock, New Brunswick, NJ; Ann Hamilton, Los Angeles, CA; Mia Hashibe, Salt Lake City, UT; Michael Goodman, Atlanta, GA; David Penson, Daniel Barocas, Nashville, TN INTRODUCTION AND OBJECTIVES: Disease-related factors influence men on active surveillance (AS) for localized prostate cancer (PCa) to discontinue AS and seek treatment, but so too may psychosocial factors. This study sought to evaluate the influence of psychosocial factors such as PCa anxiety, social support, participation in medical decision-making (PDM), and education level on patient decisions to discontinue PCa AS in the absence of disease progression.
METHODS: The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, population-based cohort study of men with localized PCa diagnosed in 2011-2012. PCa anxiety, social support, PDM, education level, and patient reasons for discontinuing AS were assessed through patient surveys. A Cox proportional hazards model examined the relationship between psychosocial variables and time to discontinuing AS. RESULTS: Of 531 AS patients, 165 (30.9%) underwent treatment after median follow-up of 37 months. Whereas 69% of patients cited only medical reasons for discontinuing AS, 31% cited at least one personal reason, and 8% cited personal reasons only. Patients with some college education discontinued AS significantly earlier (HR: 2.0, 95% CI: 1.2, 3.2) than patients with less education. PCa anxiety, social support, and PDM were not associated with seeking treatment.
CONCLUSIONS: We found that 31 percent of men who choose AS for PCa discontinue AS within 3 years. Eight percent of men who sought treatment did so in the absence of disease progression. Education, but not psychosocial factors, seems to influence seeking definitive treatment. Future research is needed to understand how factors unrelated to disease severity influence treatment decisions among AS patients in order to identify opportunities to improve adherence to AS.
